万春医药美股招股说明书(2025-11-17版)

800,000 We are offering 800,000 of our ordinary shares to Ray Beauty Group Limited pursuant to this prospectussupplement and the accompanying prospectus and a securities purchase agreement with such investor. Theoffering price is $2.50 per ordinary share. Our ordinary shares are listed on the Nasdaq Capital Market under the Investing in our ordinary shares involves a high degree of risk. Before buying any shares, you shouldreview carefully the risks and uncertainties described under the heading “Risk Factors” beginning on page S- 3of this prospectus supplement, on page5of the accompanying prospectus, under “Risk Factors” in our mostrecent annual report on Form10-K and under similar headings in the other documents that are incorporated Offering price Neither the Securities and Exchange Commission nor any state securities commission has approved ordisapproved of these securities or passed upon the adequacy or accuracy of this prospectus supplement or Delivery of the ordinary shares is expected to be made on or about November18, 2025 only in book-entryform. Prospectus Supplement TABLE OF CONTENTS ABOUT THIS PROSPECTUS SUPPLEMENT A registration statement utilizing a shelf registration process relating to the securities described in thisprospectus supplement was initially filed on FormF-3 with the Securities and Exchange Commission (the “SEC”)on June 12, 2024, and subsequently amended on FormS-3 (File No. 333-280153) on August13, 2025 and declaredeffective on August18, 2025. Under this shelf registration statement, of which this offering is a part, we may, from This document contains two parts. The first part is this prospectus supplement, which describes the terms ofthis offering of our ordinary shares by us, and also adds, updates and changes information contained in theaccompanying prospectus and the documents incorporated herein and therein by reference. The second part is theaccompanying prospectus, which gives more general information about us, some of which may not apply to thisoffering. To the extent the information contained in this prospectus supplement differs or varies from the informationcontained in the accompanying prospectus or any document filed prior to the date of this prospectus supplement andincorporated herein by reference, the information in this prospectus supplement will supersede and govern. Inaddition, this prospectus supplement and the accompanying prospectus do not contain all of the information You should rely only on the information contained in or incorporated by reference into this prospectussupplement and the accompanying prospectus. We have not authorized anyone to provide you with information thatis different. No dealer, salesperson or other person is authorized to give any information or to represent anything notcontained in this prospectus supplement and the accompanying prospectus. This prospectus supplement is not anoffer to sell or solicitation of an offer to buy these securities in any circumstances under which the offer orsolicitation is unlawful. We are offering to sell, and seeking offers to buy, our securities offered hereby only injurisdictions where offers and sales are permitted. You should not assume that the information we have included inthis prospectus supplement or the accompanying prospectus is accurate as of any date other than the date of this Unless otherwise mentioned or unless the context requires otherwise, all references in this prospectussupplement to: “BeyondSpring,” the “Company,” the “Registrant,” “us,” “we,” “our” and similar designations refer toBeyondSpring Inc. and its consolidated subsidiaries. “$” refers to United States Dollars. “Exchange Act” refers to the Securities Exchange Act of 1934, as amended. “Nasdaq” refers to the Nasdaq Capital Market. “Our shares,” “ordinary shares” and similar expressions refer to the Registrant’s ordinary shares, par value$0.0001 per share. “PRC” or “China” refer to the People’s Republic of China.“SEC” or the “Commission” refers to the United States Securities and Exchange Commission.“Securities Act” refers to the Securities Act of 1933, as amended. BeyondSpring Inc. We are a clinical stage global biopharmaceutical company focused on developing innovative therapies toimprove clinical outcomes for patients with high unmet medical needs. Our first-in-class lead asset, Plinabulin,which has been administered to over 700 cancer patients with generally good tolerability, is being developed as apotential “pipeline in a drug” in various cancer indications as a direct anti-cancer agent, and as a late stage clinicalasset in second and third line NSCLC with epidermal growth factor receptor wild type, a severe unmet medicalneed. Plinabulin binds in a unique pocket of tubulin and activates the immune defense protein GEF-H1, which leadsto indication of innate and adaptive immunity via dendritic cell maturation. We own global rights to Plinabulin in allcountries except China. We own a 57.97% interest in